Parsing Failure News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Parsing failure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Parsing Failure Today - Breaking & Trending Today

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc.


SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY
05/08/2021 | 04:47pm EDT
Send by mail :
Message :
Required fields
NEW YORK, May 08, 2021 (GLOBE NEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  CytoDyn Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY).   Such investors are advised to contact Robert S. Willoughby at
The investigation concerns whether CytoDyn and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 
On March 5, 2021, CytoDyn issued a press release providing an update on its product “Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications.”  The press release stated, in part, that “the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement ....

New York , United States , France General , Los Angeles , Abrahaml Pomerantz , Paul Santos , Roberts Willoughby , Cytodyn Inc , Pomerantz Firm , Seeking Alpha , Parsing Failure , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , லாஸ் ஏஞ்சல்ஸ் , பால் சாண்டோஸ் , ராபர்ட்ஸ் விருப்பம் , போமேரதண்தஜ் நிறுவனம் , தேடுவது ஆல்பா ,

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc.


Share this article
Share this article
NEW YORK, April 26, 2021 /PRNewswire/  Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ( CytoDyn or the Company ) (OTCMKTS: CYDY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether CytoDyn and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On March 5, 2021, CytoDyn issued a press release providing an update on its product Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications. The press release stated, in part, that the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients. Although the press release tout ....

New York , United States , France General , Los Angeles , Abrahaml Pomerantz , Paul Santos , Roberts Willoughby , Cytodyn Inc , Pomerantz Firm , Seeking Alpha , Parsing Failure , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , லாஸ் ஏஞ்சல்ஸ் , பால் சாண்டோஸ் , ராபர்ட்ஸ் விருப்பம் , போமேரதண்தஜ் நிறுவனம் , தேடுவது ஆல்பா ,